Literature DB >> 29792867

Effects of amphetamine exposure during adolescence on behavior and prelimbic cortex neuron activity in adulthood.

Luke K Sherrill1, Joshua M Gulley2.   

Abstract

Repeated exposure to psychostimulants during adolescence produces long-lasting changes in behavior that may be mediated by disrupted development of the mesocorticolimbic dopamine system. Here, we tested this hypothesis by assessing the effects of amphetamine (AMPH) and dopamine receptor-selective drugs on behavior and neuron activity in the prelimbic region of the medial prefrontal cortex (PFC). Adolescent male, Sprague-Dawley rats were given saline or 3 mg/kg AMPH between postnatal day (P) 27 and P45. In Experiment 1, locomotor behavior was assessed during adulthood following challenges with a dopamine D1 (SKF 82958) or D2 (quinpirole) receptor-selective agonist. In Experiment 2, pre-exposed rats were challenged during adulthood with AMPH and a D1 (SKF 83566) or D2 (eticlopride) receptor-selective antagonist. In Experiment 3, the activity of putative pyramidal cells in the prelimbic cortex was recorded as rats behaved in an open-field arena before and after challenge injections with AMPH and one of the antagonists. We found that compared to controls, adolescent pre-exposed rats were more sensitive to the stimulant effects of AMPH and the dopamine receptor agonists, as well as to the ability of the antagonists to reverse AMPH-induced stereotypy. Prelimbic neurons from AMPH pre-exposed rats were also more likely to respond to an AMPH challenge in adulthood, primarily by reducing their activity, and the antagonists reversed these effects. Our results suggest that exposure to AMPH during adolescence leads to enduring adaptations in the mesocorticolimbic dopamine system that likely mediate heightened response to the drug during adulthood.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adolescent; D(1)receptor; D(2)receptor; Development; Locomotor activity; Sensitization

Mesh:

Substances:

Year:  2018        PMID: 29792867      PMCID: PMC6026035          DOI: 10.1016/j.brainres.2018.05.028

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  80 in total

Review 1.  Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain.

Authors:  F I Tarazi; R J Baldessarini
Journal:  Int J Dev Neurosci       Date:  2000-02       Impact factor: 2.457

2.  Psychostimulant dependence in a community sample.

Authors:  Li-Tzy Wu; William E Schlenger
Journal:  Subst Use Misuse       Date:  2003-01       Impact factor: 2.164

3.  Reward Anticipation Is Encoded Differently by Adolescent Ventral Tegmental Area Neurons.

Authors:  Yunbok Kim; Nicholas W Simon; Jesse Wood; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2015-05-07       Impact factor: 13.382

4.  Adolescent amphetamine exposure elicits dose-specific effects on monoaminergic neurotransmission and behaviour in adulthood.

Authors:  Benoit Labonte; Ryan J McLaughlin; Sergio Dominguez-Lopez; Francis Rodriguez Bambico; Ilaria Lucchino; Rafael Ochoa-Sanchez; Marco Leyton; Gabriella Gobbi
Journal:  Int J Neuropsychopharmacol       Date:  2011-11-03       Impact factor: 5.176

5.  Repeated exposure to amphetamine during adolescence alters inhibitory tone in the medial prefrontal cortex following drug re-exposure in adulthood.

Authors:  Kush Paul; Shuo Kang; Charles L Cox; Joshua M Gulley
Journal:  Behav Brain Res       Date:  2016-04-13       Impact factor: 3.332

6.  Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence.

Authors:  Cristina Cadoni; Augusta Pisanu; Nicola Simola; Lucia Frau; Pier Francesca Porceddu; Silvia Corongiu; Christian Dessì; Annesha Sil; Antonio Plumitallo; Jadwiga Wardas; Gaetano Di Chiara
Journal:  Neuropharmacology       Date:  2017-06-08       Impact factor: 5.250

7.  Low doses of amphetamine lead to immediate and lasting locomotor sensitization in adolescent, not adult, male rats.

Authors:  Iva Z Mathews; Harm Kelly; Cheryl M McCormick
Journal:  Pharmacol Biochem Behav       Date:  2010-11-23       Impact factor: 3.533

8.  Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion.

Authors:  J C Horvitz; G Williams; R Joy
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

9.  Cognitive dysfunctions in recreational and dependent cocaine users: role of attention-deficit hyperactivity disorder, craving and early age at onset.

Authors:  Matthias Vonmoos; Lea M Hulka; Katrin H Preller; Daniela Jenni; Markus R Baumgartner; Rudolf Stohler; Karen I Bolla; Boris B Quednow
Journal:  Br J Psychiatry       Date:  2013-05-23       Impact factor: 9.319

10.  Differential roles of dopamine D1 and D2 receptor-containing neurons of the nucleus accumbens shell in behavioral sensitization.

Authors:  Nobuyuki Kai; Kayo Nishizawa; Yuji Tsutsui; Shuichi Ueda; Kazuto Kobayashi
Journal:  J Neurochem       Date:  2015-10-28       Impact factor: 5.372

View more
  3 in total

Review 1.  AMPed-up adolescents: The role of age in the abuse of amphetamines and its consequences on cognition and prefrontal cortex development.

Authors:  Sara R Westbrook; Lauren K Carrica; Asia Banks; Joshua M Gulley
Journal:  Pharmacol Biochem Behav       Date:  2020-08-20       Impact factor: 3.533

Review 2.  Peri-adolescent exposure to (meth)amphetamine in animal models.

Authors:  T J Phillips; S J Aldrich
Journal:  Int Rev Neurobiol       Date:  2021-08-20       Impact factor: 4.280

3.  Involvement of the dopaminergic system in the reward-related behavior of pregabalin.

Authors:  Yusuf S Althobaiti; Farooq M Almutairi; Fahad S Alshehri; Ebtehal Altowairqi; Aliyah M Marghalani; Amal A Alghorabi; Walaa F Alsanie; Ahmed Gaber; Hashem O Alsaab; Atiah H Almalki; Alqassem Y Hakami; Turki Alkhalifa; Ahmad D Almalki; Ana M G Hardy; Zahoor A Shah
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.